Why Is Salesforce (CRM) Down 5.5% Since Last Earnings Report?

Salesforce reported fiscal Q2 2027 non-GAAP EPS of $5.90, up 102.7% year over year and 80.4% above consensus, while revenue rose 10.8% to $11.35 billion, slightly exceeding estimates. The company raised FY2027 revenue guidance by $200 million to $46.10-$46.40 billion and lifted EPS guidance to $16.67-$16.71, supported by Agentforce and Data 360 growth, although the EPS beat included $2.53 per share from strategic-investment gains. Agentforce ARR exceeded $1.5 billion, up more than 240%, and Salesforce continued substantial capital returns through its $25 billion accelerated repurchase program; however, shares are down 5.5% since earnings and carry a Zacks Hold rating.

Analysis

CRM’s post-results weakness is rational: the apparent EPS upside is largely non-recurring, while the underlying revenue-guide increase contains limited organic uplift and acquired revenue. The key valuation question over the next 1-3 months is whether AI/data products convert from high usage growth into durable paid seat/workflow expansion without further gross-margin pressure. A stable operating-margin outlook despite increased cost of revenue implies that incremental AI monetization is not yet producing operating leverage.

The more investable positive is the booking-to-revenue setup. If current RPO growth holds near the guided rate while reported revenue remains low-double-digit, the market can begin to underwrite a reacceleration into the next fiscal year and assign a higher growth multiple. Slack and data-layer adoption potentially improve CRM’s competitive position versus NOW, MSFT and HUBS because workflow usage and proprietary customer data create switching costs; however, Microsoft’s distribution advantage remains the principal risk to standalone AI pricing.

Contrarian view: the buyback has materially reduced the share base, but it cannot indefinitely mask modest organic top-line growth or compensate for acquisition-dependent guide raises. The next earnings release is a clean catalyst: investors should focus on organic cRPO, AI/data net-new bookings, gross margin and cash-flow conversion—not headline EPS. Thesis is falsified by cRPO decelerating below low teens, AI growth failing to lift subscription growth, or FY margin guidance moving below the current target.

Key Decisions for Investors

• Maintain a tactical long CRM only into the next earnings window if the stock remains below its pre-report level; target a 8-12% rerating on confirmation of organic cRPO durability and AI monetization, with a 5-7% risk limit if cRPO or billings commentary weakens.
• Express the idiosyncratic thesis as long CRM / short IGV over 1-3 months rather than an outright software-beta position. CRM needs to demonstrate better bookings conversion than broad SaaS; exit if CRM underperforms IGV by another 5% before earnings without a fundamental revision.
• Do not underwrite the reported EPS run rate. Build estimates from subscription growth, gross margin and free-cash-flow guidance excluding investment gains and acquisition contributions; treat any further estimate increases driven by non-operating items as a sell-the-rally signal.
• Monitor NOW and MSFT enterprise-AI commentary as competitive read-throughs. Evidence that bundled Copilot/workflow products are displacing paid CRM AI deployments would warrant closing CRM longs; conversely, sustained CRM AI booking growth with stable margins supports adding after results.